Zai Lab (ZLAB) Q1 2026 earnings review
Commercial Engine Stalls, R&D Takes the Wheel
Zai Lab is undergoing a forced transition from a China commercial growth story to a global R&D pipeline play. Revenue is reversing, dropping 6% YoY to $99.6 million. The decline is driven by severe localized pricing pressures: volume-based procurement (VBP) generics crushed ZEJULA sales, and National Reimbursement Drug List (NRDL) renewal adjustments suppressed VYVGART. Consequently, the promised operating leverage has reversed, with operating losses widening to $69.4 million. The investment thesis now relies heavily on their internal pipeline, where the DLL3 ADC 'zoci' is accelerating rapidly with stellar AACR data and new big-pharma combination collaborations.
๐ Bull Case
The zocilurtatug pelitecan (zoci) clinical data is best-in-class, showing a 62.5% confirmed intracranial ORR in SCLC patients. New trial collaborations with Amgen and Boehringer Ingelheim validate its potential as a global backbone therapy.
Preparations are underway for the Q2 2026 launch of KarXT in China, targeting an addressable population of approximately 8 million schizophrenia patients. This represents a massive, untapped market for a novel mechanism.
๐ป Bear Case
The core revenue engines are failing. ZEJULA plunged 39% YoY due to generic olaparib entering the market, and VYVGART posted negative YoY growth following a pricing adjustment for NRDL renewal.
Management's previous goal of Q4 2025 profitability has evaporated. Operating leverage is reversing as revenue declines while R&D and SG&A expenses continue to grow.
โ๏ธ Verdict: ๐ด
Bearish near-term, neutral long-term. The deterioration of the China commercial business is jarring. The transition to valuing Zai Lab as a pre-revenue global biotech is underway, but pipeline potential requires patience.
Key Themes
Core Revenue Anchors Reversing
The structural headwinds in China are fully manifesting. ZEJULA sales collapsed from $49.5M in 25Q1 to $30.0M in 26Q1 due to shifting hospital utilization following generic VBP. Worse, VYVGART, previously touted as the primary growth driver, dropped to $17.6M (vs $18.1M a year ago) due to NRDL pricing adjustments. If volume cannot outpace these severe price cuts, the commercial portfolio will drag on the company's valuation.
Zoci (ZL-1310) Accelerating Toward Global Relevance
While the commercial business stalls, the global R&D engine is accelerating. Data presented at AACR 2026 showed a 62.5% intracranial ORR in SCLC patients and a 38.2% ORR across epNECs. Crucially, Zai Lab secured collaborations with Amgen (IMDELLTRA) and Boehringer Ingelheim (obrixtamig) to test zoci as a combination backbone. This significantly de-risks the asset and broadens its total addressable market.
Operating Leverage is Reversing
The narrative of disciplined financial control and shrinking losses is broken. Despite a 6% drop in revenue, R&D expenses rose to $65.6M and SG&A climbed to $65.1M. Consequently, the GAAP operating loss expanded to $69.4M from $56.3M a year ago. Adjusted loss from operations worsened to $51.9M from $37.1M. The business model currently lacks the scale to absorb both Chinese pricing pressures and global trial costs simultaneously.
Upcoming KarXT Launch
Management highlighted extensive launch preparations for KarXT in Q2 2026. With ~8 million schizophrenia patients in China, this represents a major catalyst. However, initial uptake will be fully dependent on commercial execution as the drug will lack immediate NRDL listing upon launch.
Regional Portfolio Offering Pockets of Growth
Despite top-line weakness, secondary products are accelerating. XACDURO surged to $8.6M (from $1.1M in 25Q1), driven by strong hospital adoption despite ongoing supply limitations. NUZYRA grew steadily to $16.3M from $15.1M, benefiting from deeper market penetration.
Other KPIs
Decreased from $789.6 million at the end of FY25. The cash burn trajectory is stable for now, providing an adequate runway to fund the global zoci Phase III trial, but the failure to reach profitability places renewed focus on the balance sheet's longevity.
Reversing. Product sales are deteriorating faster when stripping out currency fluctuations, underscoring the raw volume and pricing destruction in the underlying China commercial operations.
Guidance
Management continues to withhold official revenue and profitability guidance for 2026, citing competitive dynamics and pricing adjustments. This lack of visibility confirms that the commercial environment in China remains highly volatile.
Stable. The registrational DLLEVATE trial is on track to complete enrollment in the first half of 2027, setting up a potential global regulatory submission timeline for 2028.
Accelerating. First-in-human data from the global Phase 1/1b study is expected in the second half of 2026, providing the next major catalyst for the internal immunology pipeline.
Key Questions
ZEJULA Floor
With ZEJULA sales dropping 39% YoY due to generic olaparib VBP, where does management see the floor for this asset, and how much further deterioration is modeled for the remainder of 2026?
VYVGART Volume vs Price Dynamics
VYVGART posted negative YoY growth in Q1. Can management detail the exact pricing cut absorbed during the NRDL renewal, and what volume growth rate is required to return this franchise to positive growth in Q2 and beyond?
Zoci Combinations Timeline
Regarding the newly announced clinical collaborations with Amgen and Boehringer Ingelheim, what is the timeline for initiating these combination cohorts and when might investors see preliminary safety and efficacy data?